What is psoriatic arthritis? Psoriatic arthritis can occur in people who have psoriasis (scaly red and white skin patches). It affects the joints and areas where tissues attach to bone. The joints most often affected are: The outer joints of the fingers or toes. Wrists. Knees. Ankles. Lower back.
What is cicatricial alopecia? Cicatricial alopecia is a group of conditions that destroy hair follicles. Hair follicles are the part of the skin where the hair grows. The follicles are replaced with scar tissue. This means the hair will fall out and not grow back.
Is your back hurting? You’re in good company. In any 3-month period, about 1 in 4 adults in the U.S. has at least one day of back pain, mostly in the lower back. The back is a complicated structure. Its center is the spine, which is made up of 33 bones called vertebrae, stacked in a column. The nerves of the spinal cord run in a tunnel through the middle of those bones. Spongy discs between the vertebrae act as cushions. Ligaments and tendons hold everything together. A lot of things can go wrong with your back. A strained muscle
What is reactive arthritis? Reactive arthritis is pain or swelling in a joint that is caused by an infection in your body. You may also have red, swollen eyes and a swollen urinary tract. These symptoms may occur alone, together, or not at all. Most people with reactive arthritis recover fully from the first flare of symptoms and can return to regular activities 2 to 6 months later. Some people will have long-term, mild arthritis. A few patients will have long-term, severe arthritis that is difficult to control with treatment and may cause joint damage.
Two types of antibody molecules act in concert to stimulate inflammation in people with rheumatoid arthritis, according to research funded in part by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
Media Availability What: The U.S. Food and Drug Administration recently approved a new oral medication for the treatment of rheumatoid arthritis that represents a new class of drugs for the disease. The drug, tofacitinib (Xeljanz), provides a new treatment option for adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate, a standard therapy for the disease. Affecting nearly 1.5 million adults, rheumatoid arthritis is an inflammatory disease that causes pain, swelling, stiffness, and loss of function in the joints. It occurs when the immune system, which normally defends